SYNACT — SynAct Pharma AB Balance Sheet
0.000.00%
- SEK1.10bn
- SEK1.02bn
Annual balance sheet for SynAct Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 14.5 | 24 | 108 | 62.4 | 61.2 |
| Net Total Receivables | 6.46 | 10.7 | 14.7 | 12.4 | 14.4 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 21.3 | 34.9 | 140 | 75.1 | 94 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0 | 3.18 | 2.1 | 0.66 | 1.94 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 21.6 | 38.4 | 143 | 228 | 271 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.72 | 15.4 | 15 | 24.9 | 28.5 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.72 | 17.5 | 16.1 | 51.8 | 56.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 15.9 | 20.9 | 127 | 176 | 214 |
| Total Liabilities & Shareholders' Equity | 21.6 | 38.4 | 143 | 228 | 271 |
| Total Common Shares Outstanding |